|Bid||0.325 x 2900|
|Ask||0.350 x 900|
|Day's Range||0.325 - 0.342|
|52 Week Range||0.300 - 3.090|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.08|
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting. MerTK is emerging as a promising target for cancer immunotherapy. Its expression in innate immune cells is believed to negatively regulate immune responses and genetic removal of MerTK renders mice resistant to some tumors.
Celldex Therapeutics, Inc. (CLDX) presented interim data today from the Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. CD40, expressed on dendritic cells and other antigen presenting cells, has long been an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses. “We have completed four of the potential eight monotherapy dose levels and, to date, CDX-1140 has been well tolerated.
The biotech's spending cuts help it preserve cash to fund ongoing clinical studies that are key to its future success.
Celldex (CLDX) delivered earnings and revenue surprises of 46.67% and -54.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 4 cents. Losses, adjusted for non-recurring gains, were 8 cents per share. The biopharmaceutical company posted revenue ...
HAMPTON, N.J., Nov. 07, 2018 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018. “We.
The clinical-stage biotech received a spark from excitement over the release of abstracts to be presented at a major conference.
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Celldex Therapeutics Inc (NASDAQ:CLDX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CLDXRead More...
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike ...
The clinical-stage biotech sees bottom-line improvement after slashing spending following a big pipeline setback earlier this year.
Celldex (CLDX) delivered earnings and revenue surprises of 21.43% and 2.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 11 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Celldex Therapeutics, Inc. (NASDAQ: CLDX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern ...
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.
Stock Research Monitor: CARA, CLDX, and CORT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on CELG sign up now at www.wallstequities.com/registration . On Thursday, benchmark ...